BPC-157: What the Research Shows, Dosage, Side Effects & Legal Status

Key takeaways

• BPC-157 is a synthetic copy of 15 amino acids from a protein found in human gastric juice. It survives stomach acid, which is why it is sold as capsules as well as injections, and it is neither a hormone nor a growth factor.
• The evidence is almost entirely in rats and mice: about 220 PubMed papers, the large majority from one pharmacology group in Zagreb that first described the peptide in 1993. In those models it speeds healing of cut tendon, ligament, muscle and gut.
• The human evidence, in full: three uncontrolled pilot studies from one Florida clinic, covering 16 knee-pain patients surveyed by phone, 12 women with interstitial cystitis and 2 people given an infusion. No randomized trial has been published anywhere, and FDA's reviewers said so in July 2026.
• The doses on seller websites (usually 250 to 500 mcg once or twice a day) were not derived from any human study. The rodent dose was 10 mcg per kilogram, and nobody has established a dose, a route or a duration in people.
• Legal status: never approved in any country; off FDA's Category 2 list since April 15, 2026; recommended 8-6-1 by FDA's advisory committee on July 23, 2026 against the advice of FDA's own reviewers; no rule published, so no US pharmacy may compound it. Anything a clinic sells as BPC-157 today is a research vial.

BPC-157 at a glance

Also called

BPC 157, Body Protection Compound-157, pentadecapeptide BPC 157, PL 14736, Bepecin

Class

Synthetic 15-amino-acid fragment (GEPPPGKPADDAGLV) of a protein found in human gastric juice; stable in stomach acid; not a hormone and not a growth factor

Route

Sold as subcutaneous or intramuscular injection, capsules and nasal sprays; in animals it was given by injection, in drinking water and as a cream

FDA status

Never approved in any country. Placed on FDA's Category 2 list in 2023 and removed on April 15, 2026 after its nomination was withdrawn. FDA's advisory committee voted 8-6-1 on July 23, 2026 to recommend adding it to the 503A bulks list over the objection of FDA's own reviewers; no rule has been published as of October 2026, so no US pharmacy may compound it.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Not as a prescription product

Best-studied use

Healing of cut tendon, ligament, muscle and gut injuries in rodents; in humans, three small uncontrolled pilot studies (knee pain, interstitial cystitis, intravenous safety)

Typical monthly cost (telehealth, 2026)

No legal compounded product exists in the US; whatever a clinic or website charges is for an unapproved research vial with no pharmacy, label or recourse behind it

What BPC-157 is and how it is supposed to work

In 1993 a pharmacology group at the University of Zagreb reported a protein of about 40 kilodaltons isolated from human gastric juice, named it BPC for 'body protection compound', and characterized a 15-amino-acid fragment they believed carried its activity (Jozwiak 2025). That fragment, BPC 157 (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1,419), is what every vial and capsule sold today claims to contain; it is made by chemical synthesis.

Two properties explain the marketing. The peptide is unusually stable in gastric juice, where most peptides are digested within minutes, so it can in principle be swallowed (Mateescu 2026); and in the Zagreb group's hands it did something useful in almost every injury model tried, from stomach ulcers to cut tendons, which earned it the label 'stable gastric pentadecapeptide' and a reputation as a universal healer.

How it works is less settled than the sales pages suggest. No receptor has been identified. The best-supported findings:

• It activates the VEGFR2 pathway and grows blood vessels. A Taiwanese group, independent of Zagreb, showed that BPC-157 increased vessel density in chick embryo membranes and endothelial cell cultures, speeded blood-flow recovery in rats with hind-limb ischemia, and raised expression of VEGF receptor 2 and its downstream Akt-eNOS signaling (Hsieh 2017). This finding supports the healing claims and raises the cancer question discussed below, because angiogenesis is also how tumors feed themselves.
• It interacts with the nitric oxide system. In rats, BPC-157 did not change normal blood pressure but blunted the rise caused by the nitric oxide blocker L-NAME, prevented the fall caused by L-arginine, and generated nitric oxide in stomach tissue much as L-arginine did (Sikiric 1997); the Zagreb group has built much of its theory on this interaction.
• It changes how tendon cells behave. In cultured rat tendon fibroblasts it increased migration, survival under oxidative stress and outgrowth from explants through the FAK-paxillin pathway, without directly increasing proliferation; that work also came from Taiwan.

The pharmacokinetics are short. In rats and dogs the intact peptide had a half-life under 30 minutes, was broken down to ordinary amino acids, and had an intramuscular bioavailability of 14 to 19 percent in rats and 45 to 51 percent in dogs (Mateescu 2026). A peptide gone from the blood in half an hour that is said to act for days is a puzzle, not a solved mechanism, and the 2026 drug-development review that makes the point concludes that the main barrier to BPC-157 becoming a medicine is the absence of basic pharmaceutical science: no characterized formulation, no human pharmacokinetic study by mouth or under the skin (the only human data are blood measurements from two people given intravenous doses), no dosing rationale.

What the evidence actually shows

PubMed lists about 220 papers with BPC 157 in the title or abstract as of October 2026. Independent reviewers who have sorted through them agree: a 2025 systematic review from an orthopedic group found 36 eligible studies, 35 preclinical and one clinical, and a 2026 drug-development review counted fewer than 30 human subjects in total, all in uncontrolled pilot studies (Mateescu 2026).

BPC-157 claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
Heals cut tendon	D	Rats only. After Achilles transection, 10 mcg/kg, 10 ng/kg or 10 pg/kg injected daily improved load to failure, a walking-based functional index and tissue structure over 14 days versus saline. The same result at doses a million-fold apart is unusual pharmacology.	Staresinic 2003
Heals ligament and muscle	D	Rats only. After medial collateral ligament transection, daily injection, 0.16 mcg/mL in drinking water, or a cream on the site all improved healing over 90 days; the same group reports the same for transected and crushed muscle.	Cerovecki 2010
Grows new blood vessels (the mechanism behind healing claims)	D	Chick embryo membranes, cultured human endothelial cells and rat hind-limb ischemia: more vessels, faster blood-flow recovery, higher VEGFR2 expression. The basis of both the healing claims and the tumor concern.	Hsieh 2017
Treats ulcerative colitis and other gut disease	D	Many rodent models of ulcer, colitis, fistula and anastomosis from Zagreb. A Croatian company's inflammatory bowel disease trial was mentioned in papers from 2003 onward and never published; as of 2026 there is no completed Phase 2 trial, and FDA found no adequate human data when it reviewed the ulcerative colitis nomination in July 2026. Example: colon-to-skin fistulas healed faster in rats given BPC-157 in drinking water or by injection.	Klicek 2008; Mateescu 2026; Kelley Drye 2026
Relieves knee pain in humans	C	Retrospective chart review at one Florida clinic: 16 of 17 patients phoned 6 to 12 months after an intra-articular injection. 11 of 12 given BPC-157 alone and 3 of 4 given it with thymosin beta-4 reported improvement. No controls, no validated outcome measure, no imaging, dose not reported.	Lee 2021
Treats interstitial cystitis	C	12 women who had failed pentosan polysulfate had 10 mg injected around the bladder inflammation during cystoscopy; 10 rated their symptoms fully resolved after one treatment. Single arm, self-rated, one clinic.	Lee 2024
Safe in humans	D	Animal toxicology in mice, rats, rabbits and dogs found no serious toxicity, genotoxicity or embryo-fetal toxicity. In humans, 2 people received 10 mg and 20 mg infusions on consecutive days with no change in blood tests; that is the entire prospective human safety record.	Xu 2020; Lee 2025
Speeds recovery or builds muscle in athletes	D	No human study of any kind; the sports-medicine reviews of 2025 and 2026 advise against recommending it.	Mateescu 2026
Protects the heart or normalizes blood pressure	D	Rats only: no change in normal blood pressure, but drug-induced rises and falls were blunted through the nitric oxide system. No human cardiac or blood-pressure data beyond the two-person infusion pilot.	Sikiric 1997; Lee 2025
Oral BPC-157 works like the injection	D	Effective in rat drinking water in the ligament model. In humans, a Phase 1 study of 1 to 6 mg tablets registered in 2015 never reported results; no human oral pharmacokinetic data exist.	Cerovecki 2010; ClinicalTrials.gov NCT02637284

The animal literature and the one-group problem

The rodent studies are real and, within their design, consistent. In the 2003 Achilles study, rats whose tendon had been cut 5 mm above the heel received BPC-157 into the abdomen once a day from 30 minutes after surgery; over 14 days the treated tendons bore more load, the animals walked better on a functional index, and the gap filled with fibroblasts and collagen faster than in saline-treated controls (Staresinic 2003). The same group went on to report healing of transected quadriceps, crushed calf muscle, tendon detached from bone, and the medial collateral ligament, where injection, drinking water and a cream all worked over 90 days (Cerovecki 2010). Add the gut, vascular, brain and spinal cord models and you have most of the 220 papers.

Three features of that literature make pharmacologists cautious. First, it comes overwhelmingly from one laboratory. Independent groups have reproduced pieces of the picture, notably the cell and angiogenesis work from Taiwan and the toxicology and pharmacokinetics from China, but healing in intact animals has been replicated by others only occasionally, in smaller and less uniformly positive studies; a 2026 Turkish rat tendon study, discussed in our TB-500 profile, found BPC-157's biomechanical effect did not reach significance. Second, the dose-response is strange: the Zagreb studies report the same benefit at 10 micrograms, 10 nanograms and sometimes 10 picograms per kilogram, a million-fold range over which most drugs go from no effect to toxicity. Third, the models are fresh surgical injuries in young healthy rats, treated from 30 minutes after the cut. A 45-year-old with a two-year-old tendinopathy is not that rat.

The most useful independent reading is a 2025 literature and patent review by a Polish group, which catalogued the animal evidence, noted that BPC-157 is unapproved everywhere for want of adequate human studies, and asked whether a peptide that drives angiogenesis and raises nitric oxide output could promote tumor growth or oxidative damage (Jozwiak 2025). The Zagreb group published a comment defending the peptide, arguing that it controls rather than simply stimulates angiogenesis, opposes corneal neovascularization and shows anti-tumor effects in their animal models; the reviewers published a brief reply (Sikiric 2025). That exchange is the state of the science: an argument between the discovering laboratory and outside reviewers about theoretical risks, with no human data to settle it.

The human evidence, in full

Every published human study of BPC-157 as of October 2026 comes from one private clinic in Florida and the same first author, and all three appeared in Alternative Therapies in Health and Medicine.

1. Knee pain, 2021. A retrospective chart review of 17 patients given an intra-articular injection in 2019 or 2020, 16 of whom were phoned 6 to 12 months later and asked how much it had helped. Twelve had received BPC-157 alone, and 11 reported significant improvement; four had received BPC-157 with thymosin beta-4, and three improved. The authors state that no specific tools were used to measure function, stiffness or quality of life (Lee 2021). No control group, no imaging, and the abstract does not report the dose.
2. Interstitial cystitis, 2024. Twelve women aged 39 to 76 who had failed pentosan polysulfate had 10 mg of BPC-157 injected around the inflamed bladder wall during cystoscopy. Ten reported complete resolution after the single treatment and two about 80 percent improvement, on a global response questionnaire; no adverse events were reported (Lee 2024). The product came from a 503A pharmacy, which in 2024 meant compounding against FDA's Category 2 placement.
3. Intravenous safety, 2025. A 58-year-old man and a 68-year-old woman, both previous users, were given 10 mg on day one and 20 mg on day two, infused over an hour, with blood tests before and after. Nothing changed in markers of heart, liver, kidney, thyroid or glucose function, and no side effects were reported (Lee 2025).

Two more studies were registered in 2026, and neither has results: a single-arm study of an oral BPC-157 gummy in 40 adults that measured blood inflammation markers (NCT07752381, completed, no results posted), and a randomized pilot of BPC-157 after rotator-cuff repair at the University of Arkansas (NCT07803250, not yet recruiting as of October 2026). No randomized trial of BPC-157 has been published.

That is the list. The Zagreb papers from 2003 onward describe the peptide as 'in clinical trials for inflammatory bowel disease' under a Croatian company's code, PL 14736; no result of that trial has ever been published, and a 2011 paper that measured esophageal sphincter pressure in pancreatitis patients gave BPC-157 only to rats. A Phase 1 study of oral tablets in 42 healthy volunteers (1 to 6 mg once, then 3 mg every eight hours for two weeks) was registered by a Croatian company and run in Mexico in 2015 and 2016; its status is 'unknown' and no results were ever posted (NCT02637284). Twenty years of mentions, and not one published controlled trial.

What FDA's reviewers said in July 2026

BPC-157 was nominated to FDA's list of bulk substances that compounding pharmacies may use, with ulcerative colitis as the proposed use, and FDA's Pharmacy Compounding Advisory Committee discussed it on July 23, 2026. According to the FDA Law Blog's account, FDA's reviewers began with the question of what, exactly, was being nominated: the products on the market vary in amino-acid count and have no settled salt or free-base form, and identity and characterization are prerequisites to any compounding standard (HPM 2026). The staff's objections across the peptides under review, as summarized by Kelley Drye, were insufficient or nonexistent human clinical trial data, uncertainty about identity and composition, and safety concerns including immunogenicity, the risk that the immune system reacts to a foreign peptide or its impurities (Kelley Drye 2026). One member who voted no gave the reason in a sentence: there were no randomized controlled trials.

The committee nonetheless voted 8 to 6 with one abstention, twice, for the free-base and acetate forms. FDA is not bound by the vote and must complete notice-and-comment rulemaking, which Kelley Drye's lawyers write can take more than a year; as of our last check of the Federal Register on October 9, 2026 no proposed rule has appeared. The legal tracker will be updated the day it does.

What you are promised versus what is documented

A typical sales page lists tendon and ligament repair, faster recovery from injury and surgery, gut healing and 'leaky gut', reduced inflammation and joint pain, protection of the heart, liver and brain, and better mood and sleep. The evidence sorts those into three bins.

• Documented in rodents: faster healing of cut tendon, ligament and muscle; protection of the stomach and bowel lining from chemical and ischemic injury; healing of experimental fistulas and anastomoses; new blood vessel growth. Nothing in rodents with the chronic, degenerative injuries adults actually have.
• Reported in humans without controls: relief of knee pain by phone survey; improvement of interstitial cystitis after a single bladder-wall injection. Both from one clinic, with no comparison group and no objective measure.
• Not supported by any human evidence: tendon or ligament repair, surgical recovery, gut healing in any diagnosed condition, systemic anti-inflammatory effects, cardiac or neurological protection, mood, sleep, fat loss, muscle gain, longevity. These are the claims people pay for.

None of that makes BPC-157 inert; a peptide that reliably speeds tendon healing in rats deserves a proper human trial, and the orthopedic reviewers who have looked at it say the same. It means that in October 2026 nobody can tell you what it does in a person, at what dose, or at what risk.

BPC-157 versus what a clinician can actually prescribe

The common overuse tendinopathies (rotator cuff, elbow, patellar, gluteal, Achilles) are treated first with structured exercise and loading programs, and the honest summary of the specialist literature is that management 'consists of different exercise and loading programmes, therapeutic modalities and surgical interventions' whose effectiveness 'remains ambiguous' (Millar 2021). That ambiguity is what makes a peptide with dramatic rat results attractive, and also why a rat result is not enough: the trial that would show BPC-157 beats a loading program has never been run. Acute tears, ulcer disease and inflammatory bowel disease all have treatments with controlled-trial evidence. A clinician who prescribes those is practicing medicine; one who sells BPC-157 for the same problems is selling a research vial.

Dosage: what sellers quote versus what was studied

Where do the seller numbers come from? Almost certainly from the rat dose. Scale 10 mcg/kg to a 70 kg adult by body weight and you get 700 mcg a day; scale it by body surface area, the way FDA's guidance converts animal doses, and you get about 110 mcg. The 250 to 500 mcg range sits between the two. But a conversion is not a study: it says nothing about whether a subcutaneous shot reaches a tendon in a person or whether twice a day beats once. The intravenous pilot used 10 to 20 mg, forty times the seller dose; the bladder pilot used 10 mg once. Nobody has compared any of them.

On the oral question the position is symmetrical. The peptide survives gastric juice and worked in rat drinking water, so a capsule is not absurd; but human oral pharmacokinetics have never been published, the one registered tablet study vanished, and the intact peptide is cleared within about 30 minutes even when injected (Mateescu 2026). For a gut-wall target, local action is plausible; for a tendon, a swallowed dose would have to reach the bloodstream, which has not been shown in anyone.

Reading a seller's chart

A chart that says '5 mg vial, add 2 mL bacteriostatic water, 250 mcg per injection' describes a 2.5 mg/mL solution, so 250 mcg is 0.1 mL, or 10 units on a U-100 insulin syringe. We show the arithmetic so you can see what is being claimed, not because any study supports the dose; the reconstitution calculator does the math for any vial, and the injection guide explains why a vial with no verified sterility is a different risk from a pharmacy product.

Side effects, theoretical risks, and who should not use it

What is known. Very little. Formal toxicology in mice, rats, rabbits and dogs found no serious toxicity, mild local irritation, no genetic toxicity and no embryo-fetal toxicity; the one signal was a drop in creatinine in dogs at 2 mg/kg that reversed within two weeks of stopping (Xu 2020). The three human pilot studies reported no adverse events among roughly 30 participants, but none was designed to find them or followed anyone for long. People who inject research vials describe injection-site pain, nausea, dizziness, fatigue and headache; none of that has been collected systematically.

The theoretical risks, which are the ones that matter for a decision:

1. Tumor growth. BPC-157 grows new blood vessels through VEGFR2 (Hsieh 2017), and angiogenesis is what lets a tumor grow beyond a few millimeters and spread. The discovering group argues that the peptide modulates rather than drives angiogenesis and reports anti-tumor effects in animal models (Sikiric 2025); the outside reviewers were not persuaded. Nobody has studied it in people with cancer, including the undiagnosed cancers a 50-year-old may be carrying.
2. Blood pressure and circulation. The peptide acts on nitric oxide, the main regulator of vessel tone. In rats it left normal blood pressure alone and corrected drug-induced swings (Sikiric 1997); in people, nobody has measured blood pressure, heart rhythm or clotting on repeated dosing.
3. Immune reactions. Any injected peptide can provoke antibodies, and impurities and aggregates in uncharacterized products make that more likely. Immunogenicity was one of FDA's stated concerns in 2026 (Kelley Drye 2026).
4. The product itself. A research vial has no verified identity, potency or sterility; underdosed, overdosed, contaminated or a different peptide altogether are all possible.
5. Unknown long-term effects. There are no long-term human data of any kind.

Do not use BPC-157 if you have an active cancer or a recent cancer history; are pregnant, trying to conceive or breastfeeding; are a competitive athlete subject to testing; have uncontrolled blood pressure, heart disease or a clotting disorder, because the one mechanism everyone agrees on runs through the vascular system; or are unwilling to inject or swallow a product no pharmacist has checked. If you are using it and develop spreading redness, fever, hives or wheezing, stop and seek care the same day.

Legal status in the United States

The regulatory story is told in full in the legal tracker; the short version is this.

• Never approved. BPC-157 has never been a component of an approved drug anywhere, has no USP monograph, and is not on FDA's 503A bulks list, so it fails all three tests that would let a licensed pharmacy compound it.
• Category 2, then off it. FDA placed BPC-157 in Category 2 in 2023, the bin for substances that may present significant safety risks, so pharmacies stopped compounding it. On April 15, 2026 FDA removed it, with eleven other peptides, because the nominations had been withdrawn; that ended the safety flag but did not make it compoundable.
• Recommended, not permitted. On July 23, 2026 the advisory committee voted 8-6-1 to recommend BPC-157 for the bulks list over the objection of FDA's reviewers (HPM 2026). FDA must propose, take comments on and finalize a rule before any pharmacy may use it; as of October 2026 no proposed rule exists.
• 'FDA-approved for compounding' is false on both words. FDA approves drugs, not compounding, and a compounded drug is by definition not FDA-approved; BPC-157 is not even on the list that would allow compounding. A clinic using the phrase in 2026 is misinformed or misleading you.
• Research vials are unapproved drugs. FDA's 2026 warning letters to online peptide sellers state that a 'research use only' label does not protect a product whose website gives dosing instructions, injection guides or bundled bacteriostatic water. The letters go to sellers, not buyers; possessing BPC-157 is not a crime, and no one is prosecuted for injecting it.

Cost and the 'prescription' question

There is no legal compounded BPC-157 in the United States in October 2026, so there is no legitimate price to quote. What exists is a market of research-grade vials, capsules and nasal sprays, and a layer of clinics and telehealth sites that attach a consultation and a prescription to them. The prescription is cosmetic: it cannot make a non-compoundable substance compoundable, and a pharmacy that fills it is operating outside federal law. The monthly fee buys a vial of unverified content and, at best, someone to message.

What you can actually be prescribed depends on the problem. For a tendon or ligament injury: a structured rehabilitation program, analgesia, and the imaging, injections or surgery the injury calls for. For an ulcer: acid suppression and H. pylori treatment. For inflammatory bowel disease: the drugs with controlled-trial evidence, which now include biologics that put most patients into remission. The question to ask any provider is the tracker's: which pharmacy, in which state, on what legal basis? For BPC-157 there is no good answer, and a provider who gives one anyway has told you something about everything else they say.

Women, older adults and athletes

Women. The only female-specific human data are the 12 women, aged 39 to 76, in the interstitial cystitis pilot (Lee 2024). There are no data in pregnancy; the absence of embryo-fetal toxicity in animals (Xu 2020) is not reassurance in humans, and the peptide's vascular activity is reason enough to avoid it when pregnant or breastfeeding. For perimenopausal joint and tendon pain, which drives many purchases, the evidence-based options are the ones above plus, where appropriate, hormone therapy.

Older adults. More undiagnosed cancers, more vascular disease and more medications: this is the population in which the theoretical risks matter most. The two people in the intravenous pilot were 58 and 68 and tolerated single infusions; that is the entire record.

Athletes. BPC-157 has been named as an example in WADA class S0, non-approved substances, since the 2022 Prohibited List: prohibited at all times, in and out of competition, and a therapeutic use exemption is effectively unavailable. Athletes have been sanctioned for it, anti-doping laboratories have validated urine tests for it, and a four-year sanction for possession and promotion of BPC-157 with TB-500 was announced in September 2025. If you are tested, treat it as banned; our Wolverine stack page covers the combination.

Bottom line

BPC-157 is the best-studied peptide in rats that has never been properly studied in people. Twenty years of rodent healing data from one laboratory, a handful of independent mechanistic papers and three uncontrolled pilot studies from one clinic add up to a hypothesis worth testing, not a treatment. FDA's reviewers reached that conclusion in July 2026, and the committee's 8-6 vote the other way does not change the fact that no US pharmacy may compound it, no dose has been established, and no one knows what it does to a tumor, a blood vessel or an immune system over months of use.

If you have a tendon or a gut problem, the treatments with evidence are available on prescription today. If you want BPC-157 anyway, you are buying a research vial from a seller FDA has told to stop, at a dose a vendor invented, and the 'before and after' stories that sold it to you are the only evidence it has.

Frequently asked questions

+−What is BPC-157 and what does it do?

BPC-157 is a synthetic copy of 15 amino acids from a protein found in human gastric juice, first described by a pharmacology group in Zagreb in 1993. In rats and mice it speeds the healing of cut tendons, ligaments, muscle and gut lining, apparently by growing new blood vessels and modulating nitric oxide. In people, what it does is unknown: the entire published human record is three small uncontrolled pilot studies, and no randomized trial has ever been published.

+−Is BPC-157 good for gut health?

In rodents, yes, repeatedly: it protected the stomach lining from alcohol and anti-inflammatory drugs and healed experimental colitis, fistulas and bowel anastomoses. In humans there is no published trial. A Croatian pharmaceutical company tested it for inflammatory bowel disease about twenty years ago and never published the results, and FDA evaluated it for ulcerative colitis in July 2026 and found no adequate human data. If you have ulcerative colitis, Crohn's disease, ulcers or reflux, there are approved treatments with decades of trial data; BPC-157 is not an alternative to them.

+−Is BPC-157 FDA approved?

No, and it has never been approved anywhere. It is also not legally compoundable: as of October 2026 it is not on FDA's list of bulk substances that 503A pharmacies may use. It came off FDA's Category 2 safety-risk list on April 15, 2026, and FDA's advisory committee voted 8 to 6 with one abstention on July 23, 2026 to recommend adding it, but FDA's own reviewers recommended against it and FDA has not published a rule. A clinic that says BPC-157 is 'FDA-approved for compounding' is wrong on both words.

+−Can I get a BPC-157 prescription online?

A clinician can write anything on a prescription pad, but no licensed US pharmacy may fill a prescription for BPC-157 in October 2026, because the substance passes none of the three tests in federal compounding law. Telehealth companies that 'prescribe' it are either shipping research-grade vials with a prescription attached for appearances, or using a pharmacy that is breaking the rules. Ask which pharmacy, in which state, and on what legal basis; a real answer takes ten seconds.

+−Oral BPC-157 or injections: which works better?

Nobody knows, because neither has been tested properly in humans. The peptide is stable in stomach acid and worked in rats when dissolved in drinking water, which is the basis for capsules. Whether a swallowed dose reaches the bloodstream in people has never been measured; the one Phase 1 study of oral tablets, registered in 2015, never reported results. Injection delivers the peptide to the blood, but the intact peptide is gone within about 30 minutes in animals. Capsules sold as supplements are not dietary supplements in any legal sense; they are an unapproved drug in a different package.

+−What are the side effects of BPC-157?

No human study has been designed to find them. Animal toxicology in mice, rats, rabbits and dogs found no serious toxicity, no genetic toxicity and no harm to embryos, and of the three human pilot studies, two reported no adverse events and the third, the knee-pain chart review, did not report on them; about 30 people in total were followed briefly. The theoretical risks are the ones that follow from the mechanism: it grows blood vessels, which could feed a tumor; it acts on nitric oxide, which regulates blood pressure; it is a peptide that could provoke an immune response; and the vials sold online have no verified content or sterility. Long-term effects in humans have never been studied.

+−What does BPC-157 do to the heart?

In rats, the Zagreb group reports that it counteracts drug-induced arrhythmias, experimental heart attacks and the blood pressure swings caused by nitric oxide blockers. In humans, the only data are two people whose cardiac blood tests did not change after single intravenous infusions. There is no evidence that it helps or harms the human heart, and anyone with heart disease, high blood pressure or a clotting history should treat it as an unknown.

+−Does BPC-157 show up on a drug test?

It can. Anti-doping laboratories published a validated urine test for BPC-157 and its metabolite in 2017 after the peptide turned up in confiscated vials, and newer methods detect it at well under a nanogram per milliliter. WADA has named it as an example in class S0, non-approved substances, since the 2022 Prohibited List, so it is prohibited at all times, and athletes have been sanctioned for it. Routine employment drug screens do not look for it.

+−What is BPC-157 KPV?

A marketing combination of BPC-157 with KPV, a three-amino-acid fragment of alpha-melanocyte-stimulating hormone that reduces inflammation in cell and animal studies, often sold as an oral 'gut' product. Both compounds were recommended by FDA's advisory committee in July 2026 and neither may be compounded as of October 2026. There is no human study of KPV alone, let alone of the combination.

+−BPC-157 vs sermorelin: what is the difference?

They have nothing in common except the word peptide. Sermorelin is a growth hormone-releasing hormone analog with an FDA approval history and real human trials, and a licensed pharmacy can compound it on prescription. BPC-157 is a gut-derived healing peptide with rodent data, three human pilot studies and no legal compounded form. Clinics that bundle them are bundling a prescribable product with a research vial.

Sources

1. StudyStaresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21:976-83. (2003)
2. StudyCerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010;28:1155-61. (2010)
3. StudyHsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95:323-33. (2017)
4. StudySikiric P et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997;332:23-33. (1997)
5. StudyXu C et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol 2020;114:104665. (2020)
6. StudyLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27(4):8-13. (2021)
7. StudyLee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024;30(10):12-17. (2024)
8. StudyLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31(5):20-24. (2025)
9. ReviewJozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review. Pharmaceuticals (Basel) 2025;18:185 (PMC11859134). (2025)
10. SourceSikiric P et al. BPC 157 therapy: targeting angiogenesis and nitric oxide's cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Comment on Jozwiak et al. Pharmaceuticals (Basel) 2025;18:1450; with the authors' reply, Pharmaceuticals 2025;18:1451, PMID 41155566. (2025)
11. StudyCox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017 (validated urine detection method). (2017)
12. StudyKlicek R et al. Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide system. J Pharmacol Sci 2008. (2008)
13. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
14. SourceClinicalTrials.gov NCT02637284. Phase I pilot study in healthy volunteers to assess the safety and pharmacokinetics of PCO-02 (oral BPC-157 tablets): 42 participants planned, Mexico, 2015-2016; status unknown, no results posted. (2015)
15. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
16. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know. July 30, 2026. (2026)
17. ReviewMillar NL et al. Tendinopathy. Nat Rev Dis Primers 2021;7:1. (2021)